Morgan Stanley’s HilleVax HLVX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
-174,906
| Closed | -$348K | – | 8246 |
|
|
2025
Q2 | $348K | Sell |
174,906
-480,771
| -73% | -$879K | ﹤0.01% | 5628 |
|
|
2025
Q1 | $951K | Sell |
655,677
-31,702
| -5% | -$58.6K | ﹤0.01% | 5023 |
|
|
2024
Q4 | $1.42M | Buy |
687,379
+435,811
| +173% | +$818K | ﹤0.01% | 4915 |
|
|
2024
Q3 | $443K | Buy |
251,568
+193,396
| +332% | +$496K | ﹤0.01% | 5461 |
|
|
2024
Q2 | $841K | Sell |
58,172
-4,861
| -8% | -$66.8K | ﹤0.01% | 5063 |
|
|
2024
Q1 | $1.05M | Sell |
63,033
-846,977
| -93% | -$13.6M | ﹤0.01% | 4928 |
|
|
2023
Q4 | $14.6M | Buy |
910,010
+295,939
| +48% | +$3.93M | ﹤0.01% | 3613 |
|
|
2023
Q3 | $8.26M | Buy |
614,071
+21,941
| +4% | +$309K | ﹤0.01% | 3295 |
|
|
2023
Q2 | $10.2M | Sell |
592,130
-3,344
| -0.6% | -$51.8K | ﹤0.01% | 3143 |
|
|
2023
Q1 | $9.84M | Sell |
595,474
-9,839
| -2% | -$157K | ﹤0.01% | 3154 |
|
|
2022
Q4 | $10.1M | Buy |
605,313
+502,197
| +487% | +$9.07M | ﹤0.01% | 3082 |
|
|
2022
Q3 | $1.76M | Sell |
103,116
-986
| -0.9% | -$14.3K | ﹤0.01% | 4522 |
|
|
2022
Q2 | $1.14M | Buy |
+104,102
| New | +$1.24M | ﹤0.01% | 4933 |
|
Morgan Stanley's HLVX Position: Q3 2025 in Review
Morgan Stanley sold out of HilleVax (HLVX) in Q3 2025, closing a stake of 174,906 shares — an estimated $348K sold.
Morgan Stanley first reported a position in HLVX in Q2 2022 and held it in 13 quarters. The position peaked at $14.6M in Q4 2023. 1 fund tracked by Wall St. Rank holds HLVX as of Q3 2025.
- Morgan Stanley reported no remaining HilleVax position as of Q3 2025 after selling out during the quarter.
- Morgan Stanley sold 174,906 HilleVax shares in Q3 2025, an estimated $348K.
- Morgan Stanley first reported a position in HilleVax in Q2 2022 and held it in 13 quarters.
- Morgan Stanley's HilleVax position peaked at $14.6M in Q4 2023.
- 1 fund tracked by Wall St. Rank held HilleVax as of Q3 2025.
Based on Morgan Stanley's 13F filing for Q3 2025, filed 14 Nov 2025.